SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents to treat people with relapsed or refractory multiple myeloma. The collaboration with Pfizer aims to test nirogacestat plus PF‐06863135 in a Phase 1b/2 trial, while SpringWorks and Janssen will launch a Phase 1 trial investigating the combination of nirogacestat and teclistamab. Both these clinical trials are expected to launch in the first half of 2021.…
You must be logged in to read/download the full post.
The post New Nirogacestat Combos to Enter Myeloma Trials, SpringWorks Says appeared first on BioNewsFeeds.